We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The approval of the twice-daily doses was based on a reduction in serum ferritin levels, as there were no controlled trials demonstrating a direct treatment benefit. Read More
The FDA has turned down a new drug application from Blueprint Medicines for Ayvakit (avapritinib) for treatment of adults with unresectable or metastatic fourth-line gastrointestinal stromal tumor (GIST). Read More